This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
More From The Market Online
Industrial Minerals confirms historic high-grade Laverton gold results
Industrial Minerals has further confirmed the potential of its Laverton gold project in WA with a…
- Colin Sandell-Hay
- 2 mins
- 22 June 2026 14:38 (AEST)
BPM Minerals identifies Beachcomber as major gold system
BPM Minerals has discovered three new gold lodes with recently completed RC drilling at the Beachcomber…
- Colin Sandell-Hay
- 3 mins
- 22 June 2026 12:46 (AEST)
Money and Investing: Financially drained in Australia? Here’s what’s really going on
This week on Money and Investing, Mitch Olarenshaw and I break down why so many Australians are feeling financially exhausted and what you
- Andrew Baxter
- 2 mins
- 22 June 2026 13:20 (AEST)
Pioneer locks in USFS approval for large-scale Springfield drilling in ‘culmination’ of prep work
Pioneer has received approval from the USFS to execute its maiden drilling program at the Springfield…
- Isaac McIntyre
- 2 mins
- 22 June 2026 11:26 (AEST)
